Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Sarcoma 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Colorectal Neoplasms 1Chondrosarcoma 1

Interventions

pembrolizumab 5Gemcitabine 5Albumin-Bound Paclitaxel 5Specimen Handling 4Nivolumab 4Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Bevacizumab 4venetoclax 3spartalizumab 3abemaciclib 3Sirolimus 3Pemetrexed 3Paclitaxel 3Leucovorin 3Ipilimumab 3Fluorouracil 3Doxorubicin 3Cisplatin 3Bortezomib 3130-nm albumin-bound paclitaxel 3manganese chloride 2fludarabine phosphate 2fludarabine 2copanlisib 2Taxes 2Midazolam 2Irinotecan 2Interleukin-2 2Immunoglobulin G 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × birinapant × Lymphoid × Clear all
NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡